Latest publications

Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial. Blauvelt A, Simpson EL, Eyerich K, De Bruin-Weller M, Barbarot S, Lio PA et al. J Dermatolog Treat 2026 Dec; 37(1):2675726

Allergenicity of Eight Soy Products: Allergy to Soy Milk Is Most Frequent and Most Severe. Kallen EJJ, Van Dijk AM, Blaauw MN, Verhoeckx KCM, Krepel P, Van Ree R et al. Clin Exp Allergy 2026 Jun 01

A Real-world Meta-analysis Study of Disease Severity in European Patients Who Received Baricitinib for Atopic Dermatitis: Data from BioDay, SCRATCH and TREATgermany. Boesjes C, Bruin-Weller M, Zuithoff NPA, Bouhaddani SE, Haeck I, Kamsteeg M et al. Acta Derm Venereol 2026 May 27; 106

Angioedema in Primary Care: Disease Course and Its Relation to ACE Inhibitor Use. Soegiharto R, Aborah S, Boekema-Bakker N, Groenewegen IAM, Knulst AC, Van den Reek JMPA et al. Int J Dermatol 2026 May 25

The era of advanced therapeutics for pediatric atopic dermatitis - can early systemic intervention reduce the type 2 inflammatory response and modify the atopic march? Vroman F, De Graaf M et al. Curr Opin Pediatr 2026 May 07

Long-term efficacy of abrocitinib in patients with moderate-to-severe atopic dermatitis to 2 years. Gooderham MJ, Silverberg JI, De Bruin-Weller M, Kircik L, Thaçi D, Zhao Z et al. J Eur Acad Dermatol Venereol 2026 Apr 28

Translating 6-year trial safety data of upadacitinib in atopic dermatitis into clinical practice. Van der Gang LF, Zuithoff NPA, De Bruin-Weller MS et al. J Eur Acad Dermatol Venereol 2026 May; 40(5):722-723

The definition of response and inadequate response to topical corticosteroid treatment in atopic dermatitis and related skin inflammatory diseases: A GALEN ADCARE statement paper. Zuberbier T, Abuzakouk M, Angelova Fischer I, Arruda LK, Augustin M, Beck L et al. World Allergy Organ J 2026 May; 19(5):101380

Long-Term Dupilumab Treatment Is Not Associated with an Increased Overall Risk of Infections in Adults with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label 5-Year Extension Study. Beck LA, Simpson EL, Thaçi D, De Bruin-Weller M, Deleuran M, Kataoka Y et al. Adv Ther 2026 Apr 18

Summary of Research: Systemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD Registry. Paller AS, Marcoux D, Ramien M, Baselga E, De Carvalho VO, Ardusso LRF et al. Dermatol Ther (Heidelb) 2026 Apr 17

Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay. Van der Gang LF, Zuithoff NPA, Haeck IM, Harbers VEM, Stadhouders-Keet S, Politiek K et al. J Eur Acad Dermatol Venereol 2026 Apr 13

Ranking primary food allergens by specific IgE-binding and clinical relevance in Dutch adults to identify reference protein sets for allergenicity assessment. Yue SR, Chou MCL, Kallen EJJ, Knulst AC, Houben GF, Bøgh KL et al. Food Chem Toxicol 2026 Jul; 213:116094

Performance of omalizumab in patients with mast cell-mediated angioedema with and without wheals. Van der Kamp S, Soegiharto R, Sørensen JA, Demir FB, Porras NM, Matsuo Y et al. J Allergy Clin Immunol Pract 2026 Mar 12

Frequency and severity of 192 foods causing food allergy in adults. Kallen EJJ, Welsing PMJ, Nijenhuis I, Van Ree R, Knulst AC, Le TM et al. J Allergy Clin Immunol Glob 2026 Mar; 5(2):100616

Efficacy of abrocitinib and dupilumab in itch-dominant atopic dermatitis: An analysis of 2 trials. Silverberg JI, De Bruin-Weller M, Ortiz de Frutos J, Silvestre JF, Esparza B, Myers DE et al. J Eur Acad Dermatol Venereol 2026 Feb 17